Cencora Inc (COR) reported its Q4 2025 earnings, revealing an earnings per share (EPS) of $3.84, which surpassed the Wall Street estimate of $3.82 by $0.02. Revenue for the quarter reached $83.7 billion, slightly below the anticipated $84.3 billion.
The company, headquartered in Conshohocken, Pennsylvania, operates as a pharmaceutical sourcing and distribution services provider. Cencora employs 42,000 full-time staff and serves healthcare providers and pharmaceutical manufacturers to enhance patient access to products and improve care. Its operations are divided into two segments: U.S. Healthcare Solutions and International Healthcare Solutions.
Cencora's upcoming earnings reports are scheduled for May 4, 2026, with an EPS estimate of $4.9591 and revenue expectation of $80.7 billion, followed by another on August 3, 2026, projected at $4.3329 EPS and $85.9 billion in revenue.
The company will host an earnings conference call to discuss these results and provide further insights into its business performance.